INTRODUCTION {#s1}
============

*Cryptococcus* is the leading cause of meningitis in persons with AIDS \[[@CIT0001]\]. Cryptococcosis accounts for approximately 15% of AIDS-related deaths worldwide \[[@CIT0002]\]. Globally, deaths from cryptococcal meningitis are still unacceptably high despite the expanded rollout of antiretroviral therapy (ART) and increased availability of effective antifungal agents \[[@CIT0002]\]. Cryptococcal meningitis can be prevented by cryptococcal antigen (CrAg) screenings of at-risk populations with advanced AIDS and then providing preemptive fluconazole therapy \[[@CIT0003]\]; however, the optimal fluconazole dose is not known. Varying fluconazole doses between 100mg/day and 2000mg/day have been used for treatment or preemptive therapy \[[@CIT0003]\].

One of the crucial factors influencing fluconazole dosing is the in vitro minimum inhibitory concentration (MIC) of fluconazole against *Cryptococcus*. The MIC ≤8 µg/mL is considered fully susceptible to fluconazole; above this threshold, treatment outcomes could be less optimal \[[@CIT0004], [@CIT0005]\]. Fluconazole therapeutic drug monitoring is not routinely used in clinical practice due to relatively predictable pharmacokinetics and infrequent resistance of initial *Cryptococcus* isolates \[[@CIT0006]\]. However, a recent systematic review of 4995 clinical isolates in 29 studies from 1988 to 2017 revealed that fluconazole nonsusceptible *Cryptococcus neoformans* and *Cryptococcus gattii* isolates ranged from 0%--50% with a mean prevalence of 12%, and an increasing trend over time \[[@CIT0009]\]. The concentration-time area under the curve (AUC) relative to the MIC is a central pharmacodynamic principle associated with fluconazole's mycologic activity. Based on pharmacokinetic and pharmacodynamic modeling in animals, an AUC:MIC ratio ≥389 is the mean stasis endpoint desired for maximal fluconazole activity against *Cryptococcus* in mice \[[@CIT0010]\]. The correlation between the MIC distribution, steady-state fluconazole concentrations in humans, and exposure in an HIV-infected population have not been well studied. Our study aimed to characterize the MIC distribution using a systematic review of published *Cryptococcus* MICs, simulate steady-state fluconazole exposures in humans, and propose a rational fluconazole dose for different phases of cryptococcal meningitis treatment and preemptive therapy in asymptomatic CrAg-positive persons.

METHODS {#s2}
=======

We determined the MIC distribution of *Cryptococcus* from a systematic review of the literature, and distribution of fluconazole plasma concentrations from a Uganda HIV-infected cryptococcal cohort to then model the probability of achieving therapeutic fluconazole concentrations for the population as well as for specific MICs.

MIC Distribution {#s3}
----------------

We performed a systematic literature search from the MEDLINE database using key words from the Medical Subject Heading (MeSH) database. Search terms were \["fluconazole" or "antifungal agents"\] and \["*Cryptococcus*" or "*Cryptococcus gattii*" or "*Cryptococcus neoformans*" or "cryptococcosis"\] and \["microbial sensitivity test" or "fungal drug resistance"\]. The search strategy identified studies reporting the MIC distribution of fluconazole against clinical *Cryptococcus* isolates from January 1, 2000, to May 31, 2018. The inclusion criteria included experimental studies, observational studies, and case series describing fluconazole MIC distribution in clinical isolates. Environmental isolates or animal studies were excluded. Data extracted from the selected studies were year, country, the number of isolates, and the pattern of overall MIC distribution.

Plasma Fluconazole Concentration {#s4}
--------------------------------

Plasma fluconazole concentrations were determined as part of the Adjunctive Sertraline for the Treatment of HIV-associated Cryptococcal Meningitis (ASTRO-CM) trial (Clinical Trials registration number NCT01802385) \[[@CIT0013]\]. We used fluconazole plasma concentrations obtained at steady state in 92 HIV-infected Ugandan adults with cryptococcal meningitis who received 800mg of oral fluconazole daily. One to three fluconazole concentrations were measured per participant during the second week of induction of meningitis therapy and averaged within participant. The details of the protocol, including fluconazole measurement method, were described in a previous study \[[@CIT0014], [@CIT0015]\].

Fluconazole Concentration and AUC Above the MIC Prediction Model {#s5}
----------------------------------------------------------------

Fluconazole is well known to have linear pharmacokinetics \[[@CIT0011], [@CIT0016]\]. For this reason, we used a linear regression model for predicting the plasma concentrations following oral fluconazole at 100 mg, 200 mg, 400 mg, 1200 mg, 1600 mg, and 2000 mg/day from the measured concentrations following oral fluconazole 800 mg daily given as directly observed therapy while hospitalized \[[@CIT0015], [@CIT0019]\]. We performed a Monte Carlo simulation with 1 million replicates based on the normal distribution of steady-state fluconazole concentrations from the different doses. We restricted the modeled distribution to ±2 standard deviations (SD), thereby truncating at \<2.5% or \>97.5% distributions. This truncation eliminated nonsensical, negative modeled fluconazole values. We modeled the MIC distribution with 1 million replicates using a normal distribution of a log~2~ geometric mean MIC ± SD and then back transforming into the geometric MIC. The proportion of fluconazole concentration relative to MIC then was calculated from the 1 million replicates. Fluconazole's long terminal half-life leads to little variability across the dosing interval \[[@CIT0020]\], so the AUC:MIC ratio also was calculated from the simulated patients using fluconazole concentration multiplied by 24 hours and divided by MIC. Analyses were performed using Excel 2016 (Microsoft, Redmond, WA).

We summarized the proportions of simulated patients achieving plasma exposures above the MIC (relevant as a target for secondary prophylaxis). We additionally summarized proportions achieving a \>100 AUC:MIC ratio. This ratio is less than the optimal AUC:MIC ratio of 389 for induction therapy determined in a murine model using \~7 log~10~*Cryptococcus* colony forming units/g tissue \[[@CIT0010]\]. This lower target (\>100 AUC:MIC) is an approximation consistent with clinical success with consolidation therapy of 400mg/day in the setting of historically lower MICs ≤2 µg/mL and lower fungal burdens at the time of consolidation therapy.

RESULTS {#s6}
=======

*Cryptococcus* Susceptibility to Fluconazole {#s7}
--------------------------------------------

A total of 681 studies were identified and screened for *Cryptococcus* susceptibility. Only 96 studies met the inclusion criteria, 75 of these studies were excluded due to the absence of presenting MIC distribution ([Supplementary Figure 1](#sup2){ref-type="supplementary-material"}). The final quantitative synthesis included 11 049 clinical *Cryptococcus* isolates reported from 21 studies ([Table 1](#T1){ref-type="table"}) \[[@CIT0006], [@CIT0007], [@CIT0021]\]. Overall, 68% of the clinical isolates came from 2 large global studies \[[@CIT0007], [@CIT0037]\] that were collected from multiple geographic sites. All studies used broth microdilution methods for MIC determination. The MICs were normally distributed on a log~2~ scale ([Supplementary Figure 2](#sup3){ref-type="supplementary-material"}) with a geometric mean of 3.4 µg/mL and a geometric standard deviation of *±*1.53 log~2~ µg/mL. The median MIC~50~ was 4 µg/mL. A total of 1255 clinical isolates (11.3%) had MIC \>8 µg/mL with 90^th^ percentile (MIC~90~) being 16 µg/mL. When the MIC distribution was divided into 2 groups by date of publication, 13 studies (n = 9507) published in 2000--2012 and 8 studies (n = 1542) published in 2014--2018, the median MIC~50~ trended upwards from 4 µg/mL to 8 µg/mL ([Figure 1](#F1){ref-type="fig"}).

###### 

Distribution of *Cryptococcus* Clinical Isolates Minimum Inhibitory Concentrations

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author                      Year   Population     N            *Cryptococcus* Minimum Inhibitory Concentrations, µg/mL                                                                                               
  --------------------------------- ------ -------------- ------------ --------------------------------------------------------- ---------- ---------- ----------- ----------- ----------- ----------- ---------- ---------- ---------
  Cogliati \[[@CIT0021]\]           2018   Italy          295          3                                                         17         35         46          67          88          35          4          0          0

  Kassi \[[@CIT0022]\]              2018   Ivory coast    50           9                                                         14         13         8           0           1           5           0          0          0

  Worasilchai \[[@CIT0023]\]        2017   Thailand       74           0                                                         0          5          17          35          17          0           0          0          0

  Gago \[[@CIT0024]\]               2016   Spain          28           0                                                         0          0          0           0           2           8           6          4          8

  Cordoba \[[@CIT0025]\]            2016   Argentina      702          2                                                         7          8          19          43          116         256         172        63         16

  Smith \[[@CIT0026]\]              2015   Uganda         198          1                                                         2          8          20          20          39          49          37         17         5

  Van Wyk \[[@CIT0027]\]            2014   South Africa   155          0                                                         0          9          19          42          53          23          6          1          2

  Morales \[[@CIT0028]\]            2014   Brazil         40           0                                                         0          8          14          9           6           0           0          3          0

  Espinel-Ingroff \[[@CIT0007]\]    2012   Global         5733         97                                                        149        319        705         1629        1868        668         206        67         25

  Matos \[[@CIT0029]\]              2012   Brazil         60           0                                                         0          0          1           2           12          28          9          2          6

  Lockhart \[[@CIT0007]\]           2012   USA            298          0                                                         0          9          17          41          71          100         40         20         0

  Govender \[[@CIT0030]\]           2011   South Africa   487          0                                                         1          27         92          196         138         30          3          0          0

  Pfaller \[[@CIT0031]\]            2011   Global         285          0                                                         3          2          24          62          140         45          8          1          0

  Mdodo \[[@CIT0032]\]              2011   Kenya          66           0                                                         2          1          5           16          32          8           2          0          0

  Illnait-Zaragozí \[[@CIT0007]\]   2010   Cuba           19           0                                                         2          2          4           4           5           2           0          0          0

  Iqbal \[[@CIT0033]\]              2009   USA            43           0                                                         0          1          0           4           16          10          10         2          0

  Fusco-Almeida \[[@CIT0034]\]      2007   Brazil         83           0                                                         0          0          2           0           12          42          20         7          0

  Bii \[[@CIT0035]\]                2007   Kenya          80           0                                                         0          0          1           3           3           12          46         6          9

  Serena \[[@CIT0036]\]             2005   Spain          20           0                                                         0          0          1           1           1           4           2          7          4

  Pfaller \[[@CIT0037]\]            2005   Global         1811         0                                                         7          11         72          327         598         489         235        72         0

  Brandt \[[@CIT0006]\]             2001   USA            522          0                                                         0          0          77          77          77          189         85         9          8

  **Total (Cumulative %)**                                **11 049**   **112**\                                                  **204**\   **458**\   **1144**\   **2578**\   **3295**\   **2003**\   **891**\   **281**\   **83**\
                                                                       1.0%                                                      2.9%       7.0%       17.4%       40.7%       70.5%       88.6%       96.7%      99.2%      100%
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Fluconazole Minimum Inhibitory Concentration Distribution for *Cryptococcus* from Years 2001--2012 and 2014--2018](ofz369f0001){#F1}

Modeled Fluconazole Concentrations {#s8}
----------------------------------

The mean plasma fluconazole concentration at steady state in 92 patients who received 800mg of oral fluconazole from the previous study as described above was 42.6 (±21.3 SD) µg/mL (median, 41.2; interquartile range, 29.8 to 52.7 µg/mL). The predicted mean plasma fluconazole concentrations (µg/mL) are reported in [Table 2](#T2){ref-type="table"}.

###### 

Distribution of Plasma Fluconazole Concentrations and Proportion Achieving Therapeutic Concentrations

  Fluconazole Dose                         100 mg         200 mg          400 mg          800 mg           1200 mg          1600 mg           2000 mg
  ---------------------------------------- -------------- --------------- --------------- ---------------- ---------------- ----------------- -------------
  Mean plasma concentration (±SD), µg/mL   5.3 ± 2.7      10.7 ± 5.3      21.3 ± 10.7     42.6 ± 21.3      63.9 ± 31.9      85.2 ± 42.6       106 ± 53
  \% below MIC                             39.8%          20.7%           8.8%            3.3%             1.7%             1.1%              0.8%
  Mean AUC~24~ (±SD) mg\*h/L               127.8 ± 63.9   255.6 ± 127.8   511.2 ± 255.6   1022.4 ± 511.2   1533.6 ± 766.8   2044.8 ± 1022.4   2556 ± 1278
  \% AUC:MIC \> 100                        13.4%          30.6%           53.2%           74.2%            83.3%            88.3%             91.2%
  \% AUC:MIC \> 389 optimal                1.5%           6.1%            17.2%           36.3%            49.7%            59.2%             66.1%

Abbreviations: AUC, area under the curve; MIC, minimum inhibitory concentration; SD, standard deviation.

Projected Fluconazole Concentrations Above MICs {#s9}
-----------------------------------------------

The Monte Carlo simulation with 1 000 000 simulated patients based on the normal distribution pattern of MICs and measured fluconazole concentrations demonstrated the projected fluconazole concentration above MICs. Only 60% of those receiving oral fluconazole at 100 mg daily were projected to reach a therapeutic concentration in blood above the *Cryptococcus* MIC, and the remaining 40% would be expected to have subtherapeutic concentrations. For oral fluconazole at 200 mg, the percentage of predicted fluconazole concentration above MICs was 79%, 400 mg was 91%, 800 mg was 97%, 1200 mg was 98%, and 1600 mg was 99% based on the total distribution of *Cryptococcus* isolates ([Table 2](#T2){ref-type="table"}).

Projected AUC:MIC Therapeutic Ratios {#s10}
------------------------------------

The projected AUC:MIC ratio was calculated from simulated patients, using steady state concentrations. Therapeutic concentrations with AUC:MIC ratio of \>100 were present in 13% of fluconazole 100 mg, 31% of fluconazole 200 mg, 53% of fluconazole 400 mg, 74% of fluconazole 800 mg, 83% of fluconazole 1200 mg, 88% of fluconazole 1600 mg, and 91% of fluconazole 2000 mg ([Table 2](#T2){ref-type="table"}). Regarding induction therapy, the percent of AUC:MIC ratio above 389 for fluconazole 400 mg was 17%, 800 mg was 36%, 1200 mg was 50%, 1600 mg was 59%, and 2000 mg was 66% ([Figure 2](#F2){ref-type="fig"}).

![Proportion Achieving Target Fluconazole AUC:MIC Ratio](ofz369f0002){#F2}

The Projected Dose of Fluconazole Based on Given MIC {#s11}
----------------------------------------------------

Based on the given MIC, the percentage of fluconazole doses reaching therapeutic exposures above MIC can be projected ([Table 3](#T3){ref-type="table"}). For MICs ≤4 µg/mL, standard secondary prophylaxis at 200 mg/day will achieve levels above the MIC in \>90% of persons. Yet as the MIC rises to 8 µg/mL, only 70% achieve therapeutic exposures, and only 14% of persons receiving 200 mg are projected to achieve therapeutic exposures in plasma above the MIC when it is 16 µg/mL. Among *Cryptococcus* isolates with higher MICs, higher fluconazole doses would be necessary to achieve therapeutic concentrations. Overall, \>90% would achieve therapeutic exposures with 400 mg at MIC of 8 µg/mL, \>90% with 800mg at 16 µg/mL, and \>85% with 1200 mg at 32 µg/mL, and \>70% with 1600 mg at 64 µg/mL ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

###### 

Possible Rational Fluconazole Dosing Based on *Cryptococcus* Minimum Inhibitory Concentration

  *Cryptococcus* MIC                                   Fluconazole Therapy                       
  ---------------------------------------------------- --------------------- --------- --------- -----
  Current Recommendations \[[@CIT0003], [@CIT0042]\]   400--800 mg           53--74%   200 mg    79%
  Customized Recommendations                                                                     
  Unknown MIC                                          800--1200 mg          74--83%   400 mg    91%
  ≤2 µg/mL                                             400 mg                \>91%     200 mg    97%
  4 µg/mL                                              800 mg                91%       200 mg    92%
  8 µg/mL^a^                                           1200 mg               85%       400 mg    92%
  16 µg/mL                                             1600 mg               68%       800 mg    92%
  32 µg/mL                                             2000 mg               30%^b^    1200 mg   86%
  64 µg/mL                                             2000 mg               0%^b^     1600 mg   70%

Abbreviations: MIC, minimum inhibitory concentration.

^a^There are no official breakpoints for *Cryptococcus*, but the 2017 Clinical and Laboratory Standards Institute Performance Standards for Antifungal Susceptibility Testing of Yeasts guidelines for *Candida albicans* cite MICs ≥8 µg/L as considered resistant \[[@CIT0039]\]. Some microbiology laboratories may provide *Candida* susceptibility breakpoints for context, but physicians should be aware that such thresholds are not clinically validated for *Cryptococcus*. These suggestions would be relevant for settings where alternative therapies are unavailable or cost-prohibitive.

^b^For isolates with MIC ≥32 µg/mL, alternative therapy should be considered as probability of achieving therapeutic fluconazole levels is low.

Refer to [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for % above MIC and [Supplementary Table 2](#sup1){ref-type="supplementary-material"} for \>100 AUC:MIC targets.

For consolidation therapy or preemptive therapy, higher AUC:MIC ratios may be necessary but less than necessary for induction therapy. The traditional 400mg/day dose would achieve \>100 AUC:MIC ratio in \>90% of persons with a MIC of 2 µg/mL and 68% of persons with a MIC of 4 µg/mL, but only 11% of persons would achieve \>100 AUC:MIC ratio with a MIC of 8 µg/mL. As *Cryptococcus* MICs double, similar proportions achieve \>100 AUC:MIC ratio target as fluconazole doses double ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Thus, at 800 mg/day of fluconazole therapy, \>90% of persons with MIC of ≤4 µg/mL and \~68% of persons with MIC of 8 µg/mL would achieve \>100 AUC:MIC target.

DISCUSSION {#s12}
==========

In our systematic review, we found that the susceptibility to fluconazole was normally distributed with a geometric mean of 3.4 µg/mL, MIC~50~ of 4 µg/mL, and MIC~90~ of 16 µg/mL. *Cryptococcus* MIC to fluconazole appears to be increasing over time when comparing reported isolates from the year 2000--2012 versus 2014--2018. Ongoing surveillance of antifungal susceptibilities is needed. Based on steady-state fluconazole concentrations from people with advanced HIV disease in Uganda, we found that currently recommended doses are far below optimal AUC targets for induction therapy, projected in \~50% of persons receiving 1200 mg/day and 36% of persons receiving 800 mg/day. Although with induction amphotericin therapy, "optimal" consolidation therapy may not be essential with induction amphotericin therapy \[[@CIT0026]\]. Subtherapeutic concentrations below the MIC would be achieved in 40% of persons receiving 100 mg/day, 21% receiving 200 mg/day, and 9% receiving 400 mg/day. This implies among those receiving the 400 mg/day consolidation dosing, 9% would achieve levels below the MIC and 21% below the MIC when receiving secondary prophylaxis with 200 mg/day. Whether low plasma levels of fluconazole are associated with mortality is an area of further exploration.

Witt et al studied the treatment of AIDS-associated cryptococcal meningitis and found that the MIC of *Cryptococcus* is an essential factor in determining the treatment outcome \[[@CIT0038]\]. Nevertheless, the breakpoint for *Cryptococcus* species was not well established given the Clinical and Laboratory Standards Institute Performance Standards for Antifungal Susceptibility Testing of Yeasts was developed for *Candida* species \[[@CIT0039]\]. The resistance for *Candida albicans* was defined by MIC ≥8 µg/mL. Previous studies have shown that the MIC breakpoint \>8 µg/mL for *Cryptococcus* species was related to poor outcome and considered as resistant \[[@CIT0004], [@CIT0005]\]. In our systematic review, 30% of clinical isolates had MIC \>4 µg/mL and 11% had MIC \>8 µg/mL. The recent systematic review showed that the resistance rates are varied, ranging from 0%--50% with a mean resistance of 10.6% (95% confidence interval \[CI\], 5.5--15.6) for incident isolates and 24.1% (95% CI, −3.1--51.2) for relapse isolates \[[@CIT0009]\]. Historically, clinical outcomes have not been associated with different MIC breakpoints when using amphotericin \[[@CIT0005], [@CIT0026]\]; however, fluconazole monotherapy for induction meningitis therapy is associated with 70% mortality in routine care \[[@CIT0040], [@CIT0041]\]. Thus, comparing outcomes versus MIC during induction therapy likely may not be the correct metric in choosing consolidation therapy doses as the success with consolidation therapy is generally high.

The current treatment dose of fluconazole for cryptococcal infection depends on the phase of treatment and HIV infection status. In the 2010 guidelines from the Infectious Disease Society of American \[[@CIT0042]\] and the 2011 guidelines from World Health Organization (WHO) \[[@CIT0043]\], the recommended fluconazole dose was 400 mg/day for consolidation phase and 200 mg/day for maintenance phase in HIV-infected patients with cryptococcal infection. The 2018 WHO cryptococcal disease guidelines recommend 800 mg/day during consolidation therapy \[[@CIT0003]\]. Higher doses up to 1600 mg or 2000 mg/day may be preferred if an alternative therapy to amphotericin B and flucytosine is necessary in the induction phase. With asymptomatic cryptococcal antigenemia, the 2010 IDSA recommendation is fluconazole 400 mg/day \[[@CIT0042]\], whereas WHO recommends 800 mg/day \[[@CIT0003]\]. Previous studies \[[@CIT0017], [@CIT0044], [@CIT0045]\] have shown that high dose fluconazole up to 2000 mg/day is generally well tolerated. In an analysis of patients with coccidioidomycosis receiving high dose fluconazole, the cumulative incidence of the adverse effects was approximately 20% through 8 weeks and continued to increase with the longer durations of therapy \[[@CIT0046]\]. Common adverse effects observed with a higher dose of fluconazole include dry skin (17%), alopecia (16%), fatigue (11%), nausea (10%), hepatic transaminitis (6%), cheilitis (5%), and isolated alkaline phosphatase elevation (2%) \[[@CIT0045], [@CIT0046]\]. Some degree of nausea is common with fluconazole doses at or above 800 mg/day and generally can be decreased by splitting the dose twice daily. Another potential concern would be increasing drug to drug interactions, historically a concern with nevirapine, yet there are few data on dose dependency of drug to drug interactions.

The IDSA guidelines also recommended against in vitro susceptibility testing for two main reasons. The first reason is that the MIC breakpoint has not been validated well, and the second reason is the low resistance rate. Although historically accurate, triazole fungicide use in agriculture has increased exponentially worldwide, including in Sub-Saharan Africa. Tebuconazole, a commonly used agricultural triazole fungicide, readily induces cross-resistance to fluconazole in *Cryptococcus* \[[@CIT0047]\], and it is possible that agricultural azole use may be why *Cryptococcus* MICs appear to be increasing per our systematic review. Our study reports 11% of isolates to have MICs \>8 µg/mL, suggesting current dose recommendations are not adequate for all instances of *Cryptococcus* infection. The predominant focus on induction therapy mostly has ignored dosing considerations for preemptive therapy for asymptomatic CrAg-positive persons, consolidation phase of meningitis therapy, and secondary prophylaxis.

Some recommended fluconazole monotherapy doses for asymptomatic cryptococcal antigenemia potentially are subtherapeutic, based on our modeling. Among persons with cryptococcal meningitis, mortality continues to occur during consolidation therapy \[[@CIT0048], [@CIT0049]\], and relapse occurs in approximately 5% of cryptococcal patients \[[@CIT0014], [@CIT0050]\]. Although this morbidity and mortality may be viewed as expected, using subtherapeutic antifungal regimens may be adversely contributing in addition to the complexities of HIV care. Those with nonsterile Cerebrospinal fluid (CSF) at 2 weeks historically have been at clear risk of excess 10-week mortality and paradoxical immune reconstitution inflammatory syndrome \[[@CIT0049], [@CIT0051], [@CIT0052]\]. Since 2010 in Uganda, we have used an enhanced consolidation therapy of 800 mg/day through 6 weeks and ART initiation or switch \[[@CIT0048]\], and others have used 800 mg/day through 10 weeks \[[@CIT0053]\]. The duration of this enhanced dosing still may be too short and secondary prophylaxis dosing too low depending on the efficacy of the induction regimen used.

Although immune reconstitution with ART may obscure overt culture-positive relapse, the failure to eradicate *Cryptococcus* may contribute to paradoxical immune reconstitution inflammatory syndrome (IRIS) \[[@CIT0052]\], including persons having higher serum CrAg titers at the time of starting ART (at 4 weeks) being at higher risk \[[@CIT0054]\]. In Uganda, as we have increased our fluconazole consolidation therapy, our incidence of paradoxical IRIS decreased from 45% with 400 mg/day to \<15% with 800 mg/day \[[@CIT0014], [@CIT0048], [@CIT0054]\].

Based on the given *Cryptococcus* MIC, our model predicted rational fluconazole doses for consolidation therapy and preemptive therapy based on the proportion of persons with \>100 AUC:MIC. Given the current population MIC distribution, the recommended consolidation dose of 800 mg will yield \~74% of persons with \>100 AUC:MIC ratio. Yet, in dropping to 400 mg, only \~53% would achieve \>100 AUC:MIC ratio. The original rationale for decreasing preemptive therapy for cryptococcal antigenemia to 400 mg after 2 weeks was the potential drug to drug interaction with nevirapine. Nevirapine now is used rarely, and fluconazole 800 mg/day or 1200 mg/day may be a more effective choice with uptrending of MICs. We found that the appropriate dose for MIC ≥8 µg/mL likely may be higher than 800 mg, and local susceptibility patterns may inform national guidelines. Similarly, in secondary prophylaxis, a customized fluconazole dose likely should be considered for MIC of 8 µg/mL (400 mg), 16 µg/mL (800 mg), 32 µg/mL (1200 mg), and 64 µg/mL (1600 mg), or alternative therapy used; however, in low and middle income countries where there is no alternative therapy \[[@CIT0055]\], recommending use of itraconazole or voriconazole is not particularly helpful. We provide some considerations of rational fluconazole dosing for consolidation therapy and secondary prophylaxis in the absence of alternative therapies ([Table 3](#T3){ref-type="table"}).

Our study is a large systematic review that compiled the MIC distribution from more than 10 000 clinical isolates over the past 2 decades and predicted the customized fluconazole dose for the population-based MIC target, and our study has some limitations. First, the fluconazole concentrations were obtained from 1 clinical study that included 92 HIV-infected Ugandans that used the linear kinetic model for predicting the exposure from different doses. Our steady plasma concentrations were within 10%--20% of observations in US, Vietnamese, and other Ugandan patients \[[@CIT0012], [@CIT0017]\]. Second, the timing of the fluconazole level draw was variable, which either could under- or overestimate the AUC calculation, but multiple samples were averaged. Third, fungal susceptibility testing is fraught with challenges, including reproducibility as well as inoculum effects where in vivo susceptibility may differ from standardized in vitro susceptibility testing. Finally, the exact target AUC above MIC ratio for consolidation therapy is unknown, and we have made an arbitrary approximation. Human data and excellent modeling has been conducted for fluconazole induction therapy \[[@CIT0012]\], yet consolidation therapy recommendations has been derived mostly from expert opinion. Based on historical experience, the doses of fluconazole used during consolidation have been less than that used for induction fluconazole monotherapy. Even now, data are limited in the selection of consolidation therapy doses with a lack of clinical studies demonstrating strong associations between suboptimal fluconazole AUC:MIC ratio and treatment failure \[[@CIT0056]\]. This is an area of further research, requiring adequate sample sizes.

In conclusion, we found that MIC distribution of *Cryptococcus* species to fluconazole was normally distributed and there was high incident (11%) of fluconazole-"resistant" *Cryptococcus*. Moreover, the standard fluconazole doses developed in the 1990s may no longer be sufficient based on increasing fluconazole MIC. Consolidation therapy and preemptive therapy doses should likely be routinely increased to at least 800 mg/day. Using low dose fluconazole at 100 mg/day for preemptive therapy in asymptomatic CrAg-positive persons does not make rational sense, based on our current understanding of fluconazole pharmacokinetics. Clinical studies using pharmacokinetics of fluconazole and MIC distribution linked to outcomes are needed to justify the rational fluconazole dose selection. Testing *Cryptococcus* susceptibility may allow a rational selection of fluconazole dose, especially in resource-limited settings, where alternative antifungal options are limited.

Supplementary Data {#s13}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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